Compound ID | 1444
Synonym(s): Ceftaroline fosamil | Teflaro | PPI-0903M | PPI0903M | PPI 0903M | T-91825 | T91825 | T 91825 | TAK-599 | TAK599 | TAK 599
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor. PBP inhibitor; PBP2a inhibitor |
| Target Pathogen: | Active against methicillin-resistant Staphylococcus aureus and Enterobacteriaceae; indicated for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia |
| Description: | A cephalosporin |
| Institute where first reported: | Forest Laboratories, USA/ AbbVie/ Allergan/ Cerexa Inc. |
| Year first mentioned: | 2008 |
| Highest development stage: | Approved by FDA in 2010; Approved for paediatric use in 2016 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/9852981 |
| Guide to Pharmacology: | ceftaroline fosamil |
| Citations: |
|